BioCentury | Apr 18, 2020
Finance
April 17 Quick Takes: Mabworks’ $160M series C; plus RDMD, PIC, SIRS, Atomo and Lantern
...lung cancer (NSCLC). Spark leads A round for real-world evidence company RDMD Spark Capital led RDMD...
...and Garuda Ventures, as well as new investor Maveron Capital, also participated in the round. RDMD...
...initiation factor 4E Elizabeth S. Eaton and Hongjiang Li, Staff Writers Wellington Partners Mabworks Biotech Co. Ltd. Lantern Pharma Inc. RDMD...
...and Garuda Ventures, as well as new investor Maveron Capital, also participated in the round. RDMD...
...initiation factor 4E Elizabeth S. Eaton and Hongjiang Li, Staff Writers Wellington Partners Mabworks Biotech Co. Ltd. Lantern Pharma Inc. RDMD...